Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_2223



Chemical Information
Antiviral agent IDDrugRepV_2223
Antiviral agent nameMethoxsalen Drug Bank
IUPAC Name9-methoxyfuro[3,2-g]chromen-7-one PubChem
SMILES (canonical)COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2 PubChem
Molecular FormulaC12H8O4 PubChem
Molecular Weight (g/mol)216.192 PubChem
InChlInChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3 PubChem
Common NameMethoxsalen Drug Bank
Synonyms6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone | 8-Methoxy-[furano-3'.2':6.7-coumarin] | 8-Methoxy-2',3',6,7-furocoumarin | 8-Methoxy-4',5':6,7-furocoumarin | 8-Methoxyfuranocoumarin | 8-Methoxypsoralen | 8-MP | 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one | Ammoidin | Meladinine | Meloxine | Methoxalen | Methoxsalen | Méthoxsalène | O-Methylxanthotoxol | Ultra mop | Xanthotoxin | Xanthotoxine | Xanthoxin | Zanthotoxin
Structural Information
  
Clinical Information
CategoryDermatologicals
Primary Indication (Clinical trial phases)Approved Drug Bank
Biological Information
Primary Indication (Disease Category) Non Infectious Disease
Primary Indication (Disease)Psoriasis | Vitiligo
Primary Indication (Drug target/Mode of Action) Melanoma-associated antigen B3
Secondary Indication Chikungunya virus (CHIKV) NA vAc-CHIKV 26S-Rhir-EWorld Health OrganisationCDC
Secondary Indication (Approaches)Experimental
Secondary Indication (Methods)in-vitro
Secondary Indication (Model system) [cell lines/ animal models]Sf21
Secondary Indication (Mode of viral infection)Adsorption
Secondary Indication (Viral titer)2 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Drug concentration)100 μM
Secondary Indication (Cell based assay)Fusion index-Fluorescent Intensities
Secondary Indication (Change)No significant decrease
Secondary Indication (Type of Inhibition) Percentage inhibition [ 7.14420741 % ]
ReferenceWang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC, Ho YJ..Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmissio.Antiviral Res. 2016 Nov;135:81-90. doi: 10.1016/j.antiviral.2016.10.003. Epub 2016 Oct 11. PMID:27742486 PubMed
CommentNiclosamide and nitazoxanide were able to inhibit CHIKV entry and transmission, which might provide a basis for the development of novel human drug therapies against CHIKV and other alphavirus infections.